Stratatech Corp. raised $3 million to continue developing a genetically engineered human skin substitute, according to a regulatory filing.
The investment comes in the form of debt, options, warrants or other securities, according to the Securities & Exchange Commission filing. Vice president and treasurer Robert Barnard declined to comment on the round.